TRAV1-2 and immunodeficiency disease: To overcome this limitation, we investigated TRAV1-2 (Vα7.2) expression on patients’ PB CD3+ lymphocytes, which has been recently described to be severely reduced in patients with immunodeficiencies caused by V(D)J recombination and DNA repair defects (32).